Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on ALK in cancer: from function to therapeutic targeting - Nature

ALK in cancer: from function to therapeutic targeting  Nature

ALK in cancer: from function to therapeutic targeting - Nature

Click here to get full coverage on ALK and Lung Cancer - American Lung Association

ALK and Lung Cancer  American Lung Association

ALK and Lung Cancer - American Lung Association

Click here to get full coverage on ALK nasal spray approved in the UK - medwatch.com

ALK nasal spray approved in the UK  medwatch.com

ALK nasal spray approved in the UK - medwatch.com

Click here to get full coverage on UBS Affirms ‘Neutral’ Stance on Alaska Air (ALK), Expects Solid Q2 Results - Insider Monkey

UBS Affirms ‘Neutral’ Stance on Alaska Air (ALK), Expects Solid Q2 Results  Insider Monkey

UBS Affirms ‘Neutral’ Stance on Alaska Air (ALK), Expects Solid Q2 Results - Insider Monkey

Click here to get full coverage on Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data - Frontiers

Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data  Frontiers

Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data - Frontiers

Click here to get full coverage on Burnley owner ALK Capital makes Espanyol first purchase in multi-club model - SportsPro

Burnley owner ALK Capital makes Espanyol first purchase in multi-club model  SportsPro

Burnley owner ALK Capital makes Espanyol first purchase in multi-club model - SportsPro

Click here to get full coverage on Ten Years of Advances: The Story of an ALK-Positive Lung Cancer Survivor - Yale School of Medicine

Ten Years of Advances: The Story of an ALK-Positive Lung Cancer Survivor  Yale School of Medicine

Ten Years of Advances: The Story of an ALK-Positive Lung Cancer Survivor - Yale School of Medicine

Click here to get full coverage on Development of a TBK1 and ALK dual inhibitor for alleviating depressive behavior via anti-inflammatory effects - ScienceDirect.com

Development of a TBK1 and ALK dual inhibitor for alleviating depressive behavior via anti-inflammatory effects  ScienceDirect.com

Development of a TBK1 and ALK dual inhibitor for alleviating depressive behavior via anti-inflammatory effects - ScienceDirect.com

Click here to get full coverage on Alaska Air Group: Execution Needs To Catch Up, But Stock Remains Undervalued - Seeking Alpha

Alaska Air Group: Execution Needs To Catch Up, But Stock Remains Undervalued  Seeking Alpha

Alaska Air Group: Execution Needs To Catch Up, But Stock Remains Undervalued - Seeking Alpha

Click here to get full coverage on Neuronal ALKAL2 and its ALK receptor contribute to the development of colitis-associated colorectal cancer - PNAS

Neuronal ALKAL2 and its ALK receptor contribute to the development of colitis-associated colorectal cancer  PNAS

Neuronal ALKAL2 and its ALK receptor contribute to the development of colitis-associated colorectal cancer - PNAS

Click here to get full coverage on Alectinib in combination with bevacizumab as first-line treatment in ALK -rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial - Nature

Alectinib in combination with bevacizumab as first-line treatment in ALK -rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial  Nature

Alectinib in combination with bevacizumab as first-line treatment in ALK -rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial - Nature

Click here to get full coverage on Progression and Expansion of ALK Inhibitors Against NSCLC: A Dual Target Approach - ScienceDirect.com

Progression and Expansion of ALK Inhibitors Against NSCLC: A Dual Target Approach  ScienceDirect.com

Progression and Expansion of ALK Inhibitors Against NSCLC: A Dual Target Approach - ScienceDirect.com

Click here to get full coverage on RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer - Nature

RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer  Nature

RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer - Nature

Click here to get full coverage on Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials - ScienceDirect.com

Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials  ScienceDirect.com

Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials - ScienceDirect.com

Click here to get full coverage on Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance - Nature

Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance  Nature

Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance - Nature

Click here to get full coverage on GUK1 activation is a metabolic liability in lung cancer - ScienceDirect.com

GUK1 activation is a metabolic liability in lung cancer  ScienceDirect.com

GUK1 activation is a metabolic liability in lung cancer - ScienceDirect.com

Click here to get full coverage on Novel selective strategies targeting the BCL-2 family to enhance clinical efficacy in ALK-rearranged non-small cell lung cancer | Cell Death & Disease - Nature

Novel selective strategies targeting the BCL-2 family to enhance clinical efficacy in ALK-rearranged non-small cell lung cancer | Cell Death & Disease  Nature

Novel selective strategies targeting the BCL-2 family to enhance clinical efficacy in ALK-rearranged non-small cell lung cancer | Cell Death & Disease - Nature

Click here to get full coverage on Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer - Nature

Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer  Nature

Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer - Nature

Click here to get full coverage on Combined utility of genomic breakpoints and frame is a reliable predictor of ALK transcript function - Nature

Combined utility of genomic breakpoints and frame is a reliable predictor of ALK transcript function  Nature

Combined utility of genomic breakpoints and frame is a reliable predictor of ALK transcript function - Nature

Click here to get full coverage on Circulating tumor DNA in ALK-positive anaplastic large cell lymphoma: a proof-of-concept study - Nature

Circulating tumor DNA in ALK-positive anaplastic large cell lymphoma: a proof-of-concept study  Nature

Circulating tumor DNA in ALK-positive anaplastic large cell lymphoma: a proof-of-concept study - Nature

Click here to get full coverage on ALK -rearranged Non–Small Cell Lung Cancer Cystic Brain Metastases - RSNA Journals

ALK -rearranged Non–Small Cell Lung Cancer Cystic Brain Metastases  RSNA Journals

ALK -rearranged Non–Small Cell Lung Cancer Cystic Brain Metastases - RSNA Journals

Click here to get full coverage on CCN1 is a therapeutic target upregulated in EML4-ALK mutant lung adenocarcinoma reversibly resistant to alectinib - Nature

CCN1 is a therapeutic target upregulated in EML4-ALK mutant lung adenocarcinoma reversibly resistant to alectinib  Nature

CCN1 is a therapeutic target upregulated in EML4-ALK mutant lung adenocarcinoma reversibly resistant to alectinib - Nature

Click here to get full coverage on Latest Advances in Management of Advanced NSCLC with ALK or ROS1 Mutations - OncLive

Latest Advances in Management of Advanced NSCLC with ALK or ROS1 Mutations  OncLive

Latest Advances in Management of Advanced NSCLC with ALK or ROS1 Mutations - OncLive

Click here to get full coverage on First Approval for New ALK Inhibitor - American Association for Cancer Research (AACR)

First Approval for New ALK Inhibitor  American Association for Cancer Research (AACR)

First Approval for New ALK Inhibitor - American Association for Cancer Research (AACR)

Click here to get full coverage on Alaska Air (ALK) Soars 22.6%: Is Further Upside Left in the Stock? - Yahoo Finance

Alaska Air (ALK) Soars 22.6%: Is Further Upside Left in the Stock?  Yahoo Finance

Alaska Air (ALK) Soars 22.6%: Is Further Upside Left in the Stock? - Yahoo Finance

Click here to get full coverage on Alaska Air Group (ALK) Beats Stock Market Upswing: What Investors Need to Know - sharewise.com

Alaska Air Group (ALK) Beats Stock Market Upswing: What Investors Need to Know  sharewise.com

Alaska Air Group (ALK) Beats Stock Market Upswing: What Investors Need to Know - sharewise.com

Click here to get full coverage on Case Report: Metastatic colorectal cancer with ALK–CEP44 fusion and rapid resistance development - Frontiers

Case Report: Metastatic colorectal cancer with ALK–CEP44 fusion and rapid resistance development  Frontiers

Case Report: Metastatic colorectal cancer with ALK–CEP44 fusion and rapid resistance development - Frontiers

Click here to get full coverage on Cascade-responsive nano-PROTACs for tumor-specific ALK protein degradation and enhanced cancer therapy - ScienceDirect.com

Cascade-responsive nano-PROTACs for tumor-specific ALK protein degradation and enhanced cancer therapy  ScienceDirect.com

Cascade-responsive nano-PROTACs for tumor-specific ALK protein degradation and enhanced cancer therapy - ScienceDirect.com

Click here to get full coverage on Discovery of an ALK Degrader for Lorlatinib-Resistant Compound Mutations - ScienceDirect.com

Discovery of an ALK Degrader for Lorlatinib-Resistant Compound Mutations  ScienceDirect.com

Discovery of an ALK Degrader for Lorlatinib-Resistant Compound Mutations - ScienceDirect.com

Click here to get full coverage on Interstitial lung disease associated with ALK inhibitors and risk factors: an updated comparative pharmacovigilance analysis - Frontiers

Interstitial lung disease associated with ALK inhibitors and risk factors: an updated comparative pharmacovigilance analysis  Frontiers

Interstitial lung disease associated with ALK inhibitors and risk factors: an updated comparative pharmacovigilance analysis - Frontiers

Click here to get full coverage on A case of pulmonary ALK-positive histiocytosis combined with Birt-Hogg-Dubé syndrome carrying an EML4::ALK gene fusion: a case report and literature review - Frontiers

A case of pulmonary ALK-positive histiocytosis combined with Birt-Hogg-Dubé syndrome carrying an EML4::ALK gene fusion: a case report and literature review  Frontiers

A case of pulmonary ALK-positive histiocytosis combined with Birt-Hogg-Dubé syndrome carrying an EML4::ALK gene fusion: a case report and literature review - Frontiers

Click here to get full coverage on Ensartinib for EML4-ALK-positive lung adenocarcinoma with comorbid mutations in TP53, EGFR, and ERBB2: a case report - Frontiers

Ensartinib for EML4-ALK-positive lung adenocarcinoma with comorbid mutations in TP53, EGFR, and ERBB2: a case report  Frontiers

Ensartinib for EML4-ALK-positive lung adenocarcinoma with comorbid mutations in TP53, EGFR, and ERBB2: a case report - Frontiers

Click here to get full coverage on ALK-based dual inhibitors: Focus on recent development for non-small cell lung cancer therapy - ScienceDirect.com

ALK-based dual inhibitors: Focus on recent development for non-small cell lung cancer therapy  ScienceDirect.com

ALK-based dual inhibitors: Focus on recent development for non-small cell lung cancer therapy - ScienceDirect.com

Click here to get full coverage on Discovery of orally bioavailable ALK PROTACs based ceritinib against ALK positive cancers - ScienceDirect.com

Discovery of orally bioavailable ALK PROTACs based ceritinib against ALK positive cancers  ScienceDirect.com

Discovery of orally bioavailable ALK PROTACs based ceritinib against ALK positive cancers - ScienceDirect.com

Click here to get full coverage on Synthesis of novel deuterated EGFR/ALK dual-target inhibitors and their activity against non-small cell lung cancer - ScienceDirect.com

Synthesis of novel deuterated EGFR/ALK dual-target inhibitors and their activity against non-small cell lung cancer  ScienceDirect.com

Synthesis of novel deuterated EGFR/ALK dual-target inhibitors and their activity against non-small cell lung cancer - ScienceDirect.com

Click here to get full coverage on ALK-EML4 fusion in small cell lung cancer: Clinical and molecular insights from a rare case - ScienceDirect.com

ALK-EML4 fusion in small cell lung cancer: Clinical and molecular insights from a rare case  ScienceDirect.com

ALK-EML4 fusion in small cell lung cancer: Clinical and molecular insights from a rare case - ScienceDirect.com

Click here to get full coverage on Is Alaska Air Group, Inc. (ALK) the Best Airline Stock to Buy Now? - Yahoo Finance

Is Alaska Air Group, Inc. (ALK) the Best Airline Stock to Buy Now?  Yahoo Finance

Is Alaska Air Group, Inc. (ALK) the Best Airline Stock to Buy Now? - Yahoo Finance

Click here to get full coverage on Alkane Resources talks output, NMPP drilling & Mandalay merger - Proactive financial news

Alkane Resources talks output, NMPP drilling & Mandalay merger  Proactive financial news

Alkane Resources talks output, NMPP drilling & Mandalay merger - Proactive financial news

Click here to get full coverage on Case Report: ALK-rearranged mesenchymal neoplasms with S100 and CD34 co-expression: additional cases with distinct characteristics - Frontiers

Case Report: ALK-rearranged mesenchymal neoplasms with S100 and CD34 co-expression: additional cases with distinct characteristics  Frontiers

Case Report: ALK-rearranged mesenchymal neoplasms with S100 and CD34 co-expression: additional cases with distinct characteristics - Frontiers

Click here to get full coverage on Cooperative blockade of FLT3 and ALK synergistically suppresses growth of osteosarcoma | Oncogene - Nature

Cooperative blockade of FLT3 and ALK synergistically suppresses growth of osteosarcoma | Oncogene  Nature

Cooperative blockade of FLT3 and ALK synergistically suppresses growth of osteosarcoma | Oncogene - Nature

Click here to get full coverage on Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma patient with KIF5B-RET fusion resistant to alectinib - Frontiers

Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma patient with KIF5B-RET fusion resistant to alectinib  Frontiers

Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma patient with KIF5B-RET fusion resistant to alectinib - Frontiers

Click here to get full coverage on Novel ALK inhibitors containing DAAP fragments: Rational drug design and anti-tumor activity research - ScienceDirect.com

Novel ALK inhibitors containing DAAP fragments: Rational drug design and anti-tumor activity research  ScienceDirect.com

Novel ALK inhibitors containing DAAP fragments: Rational drug design and anti-tumor activity research - ScienceDirect.com

Click here to get full coverage on Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia | npj Precision Oncology - Nature

Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia | npj Precision Oncology  Nature

Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia | npj Precision Oncology - Nature

Click here to get full coverage on Highly sensitive and accurate detection of ALK-TKI resistance mutations by oligoribonucleotide interference-PCR (ORNi-PCR)-based methods - ScienceDirect.com

Highly sensitive and accurate detection of ALK-TKI resistance mutations by oligoribonucleotide interference-PCR (ORNi-PCR)-based methods  ScienceDirect.com

Highly sensitive and accurate detection of ALK-TKI resistance mutations by oligoribonucleotide interference-PCR (ORNi-PCR)-based methods - ScienceDirect.com

Click here to get full coverage on Comprehensive genomic analysis reveals molecular heterogeneity in pediatric ALK-positive anaplastic large cell lymphoma | Leukemia - Nature

Comprehensive genomic analysis reveals molecular heterogeneity in pediatric ALK-positive anaplastic large cell lymphoma | Leukemia  Nature

Comprehensive genomic analysis reveals molecular heterogeneity in pediatric ALK-positive anaplastic large cell lymphoma | Leukemia - Nature

Click here to get full coverage on EURneffy wins UK approval - The Pharma Letter

EURneffy wins UK approval  The Pharma Letter

EURneffy wins UK approval - The Pharma Letter

Click here to get full coverage on Anti-EGFR therapy can overcome acquired resistance to the third-generation ALK-tyrosine kinase inhibitor lorlatinib mediated by activation of EGFR - Nature

Anti-EGFR therapy can overcome acquired resistance to the third-generation ALK-tyrosine kinase inhibitor lorlatinib mediated by activation of EGFR  Nature

Anti-EGFR therapy can overcome acquired resistance to the third-generation ALK-tyrosine kinase inhibitor lorlatinib mediated by activation of EGFR - Nature

Click here to get full coverage on How ALK Alterations Detected at the Time of EGFR TKI Resistance Impact Treatment Decisions for Advanced-Stage NSCLC - ASCO Daily News

How ALK Alterations Detected at the Time of EGFR TKI Resistance Impact Treatment Decisions for Advanced-Stage NSCLC  ASCO Daily News

How ALK Alterations Detected at the Time of EGFR TKI Resistance Impact Treatment Decisions for Advanced-Stage NSCLC - ASCO Daily News

Click here to get full coverage on Advances of dual inhibitors based on ALK for the treatment of cancer - ScienceDirect.com

Advances of dual inhibitors based on ALK for the treatment of cancer  ScienceDirect.com

Advances of dual inhibitors based on ALK for the treatment of cancer - ScienceDirect.com

Click here to get full coverage on Proteogenomic characterization identifies clinical subgroups in EGFR and ALK wild-type never-smoker lung adenocarcinoma | Experimental & Molecular Medicine - Nature

Proteogenomic characterization identifies clinical subgroups in EGFR and ALK wild-type never-smoker lung adenocarcinoma | Experimental & Molecular Medicine  Nature

Proteogenomic characterization identifies clinical subgroups in EGFR and ALK wild-type never-smoker lung adenocarcinoma | Experimental & Molecular Medicine - Nature

Click here to get full coverage on Case Report: A novel ELMOD3-ALK and EML4-ALK double-fusion responses to neoadjuvant alectinib in a lung adenocarcinoma patient - Frontiers

Case Report: A novel ELMOD3-ALK and EML4-ALK double-fusion responses to neoadjuvant alectinib in a lung adenocarcinoma patient  Frontiers

Case Report: A novel ELMOD3-ALK and EML4-ALK double-fusion responses to neoadjuvant alectinib in a lung adenocarcinoma patient - Frontiers

Click here to get full coverage on Allium cepa bioactive phytochemicals as potent ALK (Anaplastic lymphoma kinase) inhibitors and therapeutic agents against non-small cell lung cancer (NSCLC): A computational study - ScienceDirect.com

Allium cepa bioactive phytochemicals as potent ALK (Anaplastic lymphoma kinase) inhibitors and therapeutic agents against non-small cell lung cancer (NSCLC): A computational study  ScienceDirect.com

Allium cepa bioactive phytochemicals as potent ALK (Anaplastic lymphoma kinase) inhibitors and therapeutic agents against non-small cell lung cancer (NSCLC): A computational study - ScienceDirect.com

Click here to get full coverage on Revolutionary Needle-Free Alternative to EpiPen Approved in UK: EURneffy Changes Anaphylaxis Treatment - Stock Titan

Revolutionary Needle-Free Alternative to EpiPen Approved in UK: EURneffy Changes Anaphylaxis Treatment  Stock Titan

Revolutionary Needle-Free Alternative to EpiPen Approved in UK: EURneffy Changes Anaphylaxis Treatment - Stock Titan

Click here to get full coverage on Revisiting ALK (D5F3) immunohistochemistry: Insights into focal staining and neuroendocrine differentiation - Wiley Online Library

Revisiting ALK (D5F3) immunohistochemistry: Insights into focal staining and neuroendocrine differentiation  Wiley Online Library

Revisiting ALK (D5F3) immunohistochemistry: Insights into focal staining and neuroendocrine differentiation - Wiley Online Library

Click here to get full coverage on Coexistence of a novel SV2B-ALK EML4-ALK double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review - Frontiers

Coexistence of a novel SV2B-ALK EML4-ALK double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review  Frontiers

Coexistence of a novel SV2B-ALK EML4-ALK double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review - Frontiers

Alaska Air Group Inc (ALK)

Price Chart

Key Statistics

Technicals

About ALK

Latest News

ALK in cancer: from function to therapeutic targeting - Nature

ALK and Lung Cancer - American Lung Association

ALK nasal spray approved in the UK - medwatch.com

Advanced Charts

Top Gainers

Top Losers